03:56 PM EST - Acasti Pharma : announced that it has signed an agreement with a world leader in natural based specialty chemicals for the manufacturing of CaPre® clinical material in expectation of upcoming Pharmacokinetics and phase III clinical trials in the USA and to substantiate its upcoming submission of an Investigational New Drug filing. Acasti Pharma
shares V.APO are trading up $0.15 at $4.05.
